De-risk your antibody characterization workflows with high-quality, multi-parameter stability data from Prometheus Panta

May 23, 2024

Developability profiles for monoclonal antibodies require stability data to inform on rational design and selection of therapeutic constructs that are most likely to succeed in the clinic.

Prometheus Panta – a tool for multi-parameter stability characterization of biologics – delivers high-quality data on your constructs with reliable, high-resolution data on many stability parameters with low sample consumption.

In this webinar, learn more about the technology inside and how the discovery group at Merck & Co. used Prometheus Panta to assess multiple developability characteristics of their mAb therapeutics, and gained deeper insight into the quality attributes of their candidates.

You’ll learn:

  •  What technologies are in the Prometheus Panta instrument, and what they tell you about your protein-based therapeutics
  • How the Protein Science team from Merck & Co. used Prometheus Panta to rank and characterize engineered antibodies
  • Why high-resolution, trustworthy data is so critical to a successful developability work

Related resources:

Learn more about the work of the Protein Science Group at Merck & Co. in this application note

Explore Prometheus Panta in a short 10 min video walthrough

Previous
How Pierre Fabre Laboratories enhances their antibody developability platform
How Pierre Fabre Laboratories enhances their antibody developability platform

Learn how Pierre Fabre uses multi-parameter stability measurements of mAb libraries on Prometheus Panta to ...

Up next
Why Dr. Elsa Wagner from Pierre Fabre chose Prometheus Panta for mAbs developability assessment
Why Dr. Elsa Wagner from Pierre Fabre chose Prometheus Panta for mAbs developability assessment

Read why scientist Dr. Elsa Wagner chose the Prometheus Panta instrument with simultaneous measurements of ...

Want to see more
biologics content?

Explore resources